# An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy

> **NCT02090959** · PHASE3 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 219 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne
- Muscular Dystrophies
- Muscular Disorders, Atrophic
- Muscular Diseases
- Musculoskeletal Diseases
- Neuromuscular Diseases
- Nervous System Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT02090959
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-20
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-06-12
- **Target enrollment:** 219 (ACTUAL)
- **Why stopped:** Sponsor decision due to commercial availability of ataluren.
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090959, "An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02090959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*